Quintiles has added Aaron Ciechanover, recipient of the Nobel Prize in Chemistry in 2004, to its translational research and development scientific advisory board. Ciechanover received the Nobel Prize, along with two other people, for discovery of ubiquitin-mediated protein degradation.
Edward Hu has been named as chief financial officer at WuXi PharmaTech. Hu joined WuXi in 2007 and served as acting chief financial officer from February 2009 to May 2010. Before joining WuXi he worked at Tanox. Hu replaces Hao Zhou who is leaving to pursue other opportunities.
Ricerca Biosciences has added Carlos Martinez Manchado to its analytical chemistry department. Manchado previously worked at Azopharma.
Alberto Hidalgo has joined Bioanalytical Systems, Inc (BASi) as vice president (VP), business development and marketing. Hidalgo has previously worked at Covance Central Laboratory Services and Eli Lilly.
NeoGenomics has appointed Grant Carlson as VP of business development. Carlson was president, CEO of co-founder of Calgenex before joining NeoGenomics as VP, sales and marketing.
Mark Smits is replacing Carlson as VP, sales and marketing. Smits worked at Abbott Diagnostic Division for more than 25 years before joining Thermo Fisher.
Amy Karren, director of scientific development at Nelson Laboratories, has been elected to serve a five-year term on the US Pharmacopeia Convention (USP) small molecules monographs 1 committee.
Eliassen Group has appointed Dave MacKeen as CEO. Mackeen replaces Ken Dreyer, who will now work as executive vice chairman of the board of directors. Before becoming CEO Mackeen held a number of positions at Eliassen, including chief financial officer.
The company has also named Mike McBrierty as chief operating officer of the technology staffing division. McBrierty joined Eliassen in 1996 having worked at Sullivan & Cogliano for 11 years.
Evelyn Graham has joined Worldwide Clinical Trials as EVP, global business development. Graham is the former CEO of TorreyPines Therapeutics and has also worked at Purdue Pharma and Ingenix Pharmaceutical Services.